Previous 10 | Next 10 |
Vascular Biogenics Ltd (VBLT) Q2 2020 Earnings Conference Call August 13, 2020, 08:30 ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO & Director Amos Ron - CFO & Company Secretary Conference Call Participants Kevin DeGeeter - Oppenheimer ...
VBL Therapeutics ( VBLT ) Q2 results : More news on: Vascular Biogenics Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
TEL AVIV, Israel, Aug. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2020, and provided a corporate update. “We have made excellent progress advancing our lead candidate VB-111 during 2020,...
The independent Data Safety Monitoring Committee (DSMC) has completed second interim analysis for VBL Therapeutics' ( VBLT -5.0% ) ofranergene obadenovec (VB-111) Phase 3 (( OVAL )) trial in platinum-resistant ovarian cancer and recommended that the study continue unmodifi...
EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35% on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-...
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...
Evoke Pharma (NASDAQ: EVOK ) +85% on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...
TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying establish...
VBL Therapeutics (NASDAQ: VBLT ) announces new data on its proprietary anti-MOSPD2 antibodies in rheumatoid arthritis (RA). The results are being virtually presented at EULAR. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...